Microbiological and Structural Characterisation of Novel Putative Drug Targets in Helicobacter pylori

Helicobacter pylori is a gastric pathogen that infects approximately 50% of the world's population. Infection with H. pylori causes stomach inflammation, peptic ulcer and gastric cancer. The success rate of the current H. pylori treatment regimen has decreased over the past decades, mainly due to antibiotic resistance. Because of the increasing antibiotic resistance, the World Health Organization listed H. pylori as a high-priority pathogen for the development of new drug targets. My PhD works mainly focused on the mechanism of substrate-binding proteins by which H. pylori uptakes essential nutrients from extra-cellular source for its growth and pathogenesis. Utilizing the microbiology and structural biology techniques, I have discovered some novel putative drug targets in H. pylori.